Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 1849 - 1856 of 12026 results
OpEd: Navigating Fiduciary Duties Amid The Rise Of Anti-ESG Rulemaking
February 14, 2023| News
Employers Making FLSA Administrative Exemption Classification Determinations Should Make Note of a New First Circuit Case
February 13, 2023| Blog| Viewpoint
The Future Of AI: Will It Change Life In NYC For Better Or Worse?
February 13, 2023| News
Startup Workers Wrestle With Stock Options as Company Exits Stall
February 13, 2023| News
Some Companies Are Tying Executive Compensation To Hitting DE&I Goals, But Is It A Good Idea?
February 13, 2023| News
Remote Work Pay Transparency Captured in Tweaks to New York Law
February 13, 2023| News
FDA’s Digital Health High Notes from 2022
February 13, 2023| Blog| Viewpoint
Mintz Venture Watch — Volume 4: A Report on Deal Trends from 2022
February 9, 2023| Article| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
The Evolving Global Digital Infrastructure: Data Centers, AI, and the Next Wave of Connectivity
New York, NY
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|